Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial)
Kazunori Takada,Kenichiro Imai,Takanori Yamada,Ken Ohata,Takashi Kanesaka,Yasuaki Nagami,Yasushi Yamasaki,Hideki Kobara,Yasuhiro Inokuchi,Akiko Chino,Shinjiro Yamaguchi,Hisatomo Ikehara,Takuji Kawamura,Yohei Yabuuchi,Yasuhiko Mizuguchi,Hiroaki Ikematsu,Chizu Yokoi,Santa Hattori,Kazuya Ohno,Yashiro Yoshizawa,Masakatsu Fukuzawa,Yosuke Tsuji,Jun Konishi,Takeshi Yamamura,Satoshi Osawa,Shiro Oka,Takuto Hikichi,Kazutomo Togashi,Kingo Hirasawa,Toshio Uraoka,Yoji Takeuchi,Hideyuki Chiba,Yoriaki Komeda,Hisashi Doyama,Mari S. Oba,Yutaka Saito
DOI: https://doi.org/10.1186/s12876-024-03130-0
2024-02-10
BMC Gastroenterology
Abstract:Endoscopic resection is widely accepted as a local treatment for rectal neuroendocrine tumors sized ≤ 10 mm. However, there is no consensus on the best method for the endoscopic resection of rectal neuroendocrine tumors. As a simplified endoscopic procedure, endoscopic submucosal resection with a ligation device (ESMR-L) indicates a histologically complete resection rate comparable to that of endoscopic submucosal dissection (ESD). We hypothesized that ESMR-L than ESD would be preferred for rectal neuroendocrine tumors. Hence, this trial aimed to verify whether ESMR-L is non-inferior to ESD in terms of histologically complete resection rate.
gastroenterology & hepatology